A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

被引：0

作者：

Pandite, L

Burris, HA

Jones, S

Wilding, G

Taylor, C

Versola, MJ

Smith, DA

Stead, A

Koch, KM

Spector, NL

机构：

[1] GlaxoSmithKline, Res Triangle Pk, NC USA

[2] Sarah Cannon Canc Ctr, Nashville, TN USA

[3] Wisconsin Comprehens Canc Ctr, Madison, WI USA

[4] Arizona Canc Ctr, Tucson, AZ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3179

引用

页码：238S / 238S

页数：1

共 50 条

[41] A phase I and pharmacokinetic study of PEG-camptothecin in patients with advanced solid tumors.
Hao, D
Tolcher, AW
Rizzo, JD
Ochoa, L
McCreery, H
Schwartz, GH
Patnaik, A
Denis, LJ
Hammond, LA
Hidalgo, M
Kwiatek, J
McGuire, J
Rowinsky, EK
CLINICAL CANCER RESEARCH, 2000, 6 : 4513S - 4513S
[42] Pharmacokinetic (PK) comparison of two infusion (inf) schedules (sch) of irofulven in advanced solid tumors.
Lokiec, F
Alexandre, J
Raymond, E
Brain, E
Chieze, S
Lagree, S
Smith, S
Vanderbilt, K
Cvitkovic, E
Misset, J
CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3698S - 3699S
[43] A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.
Burris, Howard A.
Patel, Manish R.
Cho, Daniel C.
Clarke, Jeffrey Melson
Gutierrez, Martin
Zaks, Tal Z.
Frederick, Joshua
Hopson, Kristen
Mody, Kinjal
Binanti-Berube, Alverina
Robert-Tissot, Celine
Goldstein, Bree
Breton, Ben
Sun, Jing
Zhong, Shan
Pruitt, Scott K.
Keating, Karen
Meehan, Robert S.
Gainor, Justin F.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.
Ajani, Jaffer A.
Javle, Milind M.
Eng, Cathy
Fogelman, David R.
Anderson, Barry Douglas
Zhang, Chun
Iizuka, Kenzo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).
Jones, SF
Hainsworth, JD
Spigel, DR
Peacock, NW
Willcutt, NT
Pandite, LN
Versola, PMJ
Koch, KM
Greco, F
Burris, HA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 147S - 147S
[46] Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors.
Lankheet, Nienke A. G.
Kloth, Jacqueline S. L.
Gadellaa-van Hooijdonk, Christa G. M.
Cirkel, Geert A.
Mathijssen, Ron H. J.
Lolkema, Martijn P. J. K.
Schellens, Jan H. M.
Voest, Emile E.
Sleijfer, Stefan
Beijnen, Jos H.
Huitema, Alwin D. R.
Steeghs, Neeltje
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[47] Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKO-602 (S-CKD602) in patients with advanced solid tumors.
Zamboni, WC
Ramalingam, S
Friedland, DM
Belani, CP
Stoller, RG
Modi, NB
Nath, RP
Tonda, ME
Strychor, S
Ramanathan, RK
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 152S - 152S
[48] Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors.
Faivre, Sandrine J.
Olszanski, Anthony J.
Weigang-Koehler, Karin
Riess, Hanno
Peng, Guangbin
Callies, Sophie
Benhadji, Karim Adnane
Raymond, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[49] A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.
Reddy, NM
Zamboni, WC
Creaven, PJ
Ramnath, N
Javle, MM
Strychor, S
Repinski, TVW
Zamboni, BA
Schwarz, JK
French, RA
Fakih, MG
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 146S - 146S
[50] A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.
Fakih, MG
Zamboni, WC
Ramnath, N
Javie, MM
Schwarz, JK
French, RA
Regal, LL
Gorenflo, RK
Creaven, PJ
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 150S - 150S

← 1 2 3 4 5 →